Trimethadione

CAS No. 127-48-0

Trimethadione( NSC 15799 | NSC 169503 )

Catalog No. M11145 CAS No. 127-48-0

Trimethadione is an oxazolidinedione anticonvulsant; commonly used to treat epileptic conditions.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
100MG 44 In Stock
200MG 63 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Trimethadione
  • Note
    Research use only, not for human use.
  • Brief Description
    Trimethadione is an oxazolidinedione anticonvulsant; commonly used to treat epileptic conditions.
  • Description
    Trimethadione is an oxazolidinedione anticonvulsant; commonly used to treat epileptic conditions.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    NSC 15799 | NSC 169503
  • Pathway
    GPCR/G Protein
  • Target
    Calcium Channel
  • Recptor
    Calcium Channel
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    127-48-0
  • Formula Weight
    143.14
  • Molecular Formula
    C6H9NO3
  • Purity
    >98% (HPLC)
  • Solubility
    soluble in Water
  • SMILES
    O=C(N1C)OC(C)(C)C1=O
  • Chemical Name
    3,5,5-trimethyl-1,3-oxazolidine-2,4-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Shen H, et al. Hear Res. 2007 Apr;226(1-2):52-60.
molnova catalog
related products
  • TTA-A2

    TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating.?

  • NNC 55-0396

    A potent and selective T-type calcium channel antagonist that blocks recombinant alpha(1)G T-type channels in human embryonic kidney 293 cellswith IC50 of 7 uM.

  • ACT 709478

    ACT 709478 is a potent, selective, orally-bioavailable, brain penetrant T-type calcium channel blocker with IC50 of 6.4, 18, and 7.5 nM for Cav3.1, Cav3.2, and Cav3.3 channels respectively.